Literature DB >> 7893405

Neuroleptics block high- but not low-dose heroin place preferences: further evidence for a two-system model of motivation.

K Nader1, A Bechara, D C Roberts, D van der Kooy.   

Abstract

The researchers studied whether 2 separate motivational systems in the brain underlie the rewarding effects of morphine. The brainstem tegmental pedunculopontine nucleus (TPP) is involved in mediating the motivational effects of opiates in nondeprived (drug-naive) rats, whereas dopamine transmission is necessary in mediating the motivational effects of opiates in deprived rats (opiate withdrawal). The results show that heroin's motivational properties obey the same boundary between a nondeprived and a deprived motivational state. Bilateral ibotenic acid lesions of the TPP blocked the acquisition of a place preference for an environment paired with 0.05 mg/kg heroin (a dose that induces no withdrawal aversion) but had no effect on place preference for an environment paired with 0.5 mg/kg heroin (a dose that does induce withdrawal aversion). Dopamine antagonist pretreatment produced the opposite pattern of results.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7893405     DOI: 10.1037//0735-7044.108.6.1128

Source DB:  PubMed          Journal:  Behav Neurosci        ISSN: 0735-7044            Impact factor:   1.912


  13 in total

1.  Blockade of muscarinic acetylcholine receptors in the ventral tegmental area prevents acquisition of food-rewarded operant responding in rats.

Authors:  Ruth Sharf; Jennifer McKelvey; Robert Ranaldi
Journal:  Psychopharmacology (Berl)       Date:  2006-03-09       Impact factor: 4.530

2.  Opiate Exposure State Controls a D2-CaMKIIα-Dependent Memory Switch in the Amygdala-Prefrontal Cortical Circuit.

Authors:  Laura G Rosen; Jordan Zunder; Justine Renard; Jennifer Fu; Walter Rushlow; Steven R Laviolette
Journal:  Neuropsychopharmacology       Date:  2015-07-15       Impact factor: 7.853

Review 3.  Opioid-induced rewards, locomotion, and dopamine activation: A proposed model for control by mesopontine and rostromedial tegmental neurons.

Authors:  Stephan Steidl; David I Wasserman; Charles D Blaha; John S Yeomans
Journal:  Neurosci Biobehav Rev       Date:  2017-09-23       Impact factor: 8.989

Review 4.  The neurobiology of opiate motivation.

Authors:  Ryan Ting-A-Kee; Derek van der Kooy
Journal:  Cold Spring Harb Perspect Med       Date:  2012-10-01       Impact factor: 6.915

5.  Measuring the incentive value of escalating doses of heroin in heroin-dependent Fischer rats during acute spontaneous withdrawal.

Authors:  Katharine M Seip; Brian Reed; Ann Ho; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2011-07-07       Impact factor: 4.530

6.  Effects of haloperidol in a response-reinstatement model of heroin relapse.

Authors:  A Ettenberg; L A MacConell; T D Geist
Journal:  Psychopharmacology (Berl)       Date:  1996-04       Impact factor: 4.530

7.  Deprivation state switches the neurobiological substrates mediating opiate reward in the ventral tegmental area.

Authors:  K Nader; D van der Kooy
Journal:  J Neurosci       Date:  1997-01-01       Impact factor: 6.167

Review 8.  Opiate versus psychostimulant addiction: the differences do matter.

Authors:  Aldo Badiani; David Belin; David Epstein; Donna Calu; Yavin Shaham
Journal:  Nat Rev Neurosci       Date:  2011-10-05       Impact factor: 34.870

9.  Striatal Dopamine Release in Response to Morphine: A [11C]Raclopride Positron Emission Tomography Study in Healthy Men.

Authors:  Primavera A Spagnolo; Alane Kimes; Melanie L Schwandt; Ehsan Shokri-Kojori; Shantalaxmi Thada; Karran A Phillips; Nancy Diazgranados; Kenzie L Preston; Peter Herscovitch; Dardo Tomasi; Vijay A Ramchandani; Markus Heilig
Journal:  Biol Psychiatry       Date:  2019-03-15       Impact factor: 13.382

Review 10.  Tales from the dark side: do neuromodulators of drug withdrawal require changes in endocannabinoid tone?

Authors:  Erik B Oleson; Roger Cachope; Aurelie Fitoussi; Joseph F Cheer
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-08-01       Impact factor: 5.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.